Journal of Pharmaceutical and Biomedical Analysis 90 (2014) 192–197

Contents lists available at ScienceDirect

Journal of Pharmaceutical and Biomedical Analysis

journal homepage: www.elsevier.com/locate/jpba

Short communication

Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients

Ana C. Miranda Bastos [a,b,c], Stefaan J. Vandecasteele [d], Paul M. Tulkens [a,c], Anne Spinewine [b,c], Françoise Van Bambeke [a,c,*]

[a] Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
[b] Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
[c] Center for Clinical Pharmacy, Université catholique de Louvain, Brussels, Belgium
[d] Department Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium

ARTICLE INFO

Article history:
Received 3 September 2013
Accepted 4 December 2013
Available online 12 December 2013

Keywords:
HPLC-UV
Validation
Haemodialysis
Temocillin
Therapeutic drug monitoring

ABSTRACT

Therapeutic drug monitoring of β-lactams can be useful for the optimization of therapy, especially when little reference data exist on actual pharmacokinetic profiles such as in patients undergoing haemodialysis. There is no reported validated method for temocillin assay in serum samples, and preliminary studies evidenced potential for interferences by acidic metabolites and co-administered drugs in patients with advanced kidney failure. This paper describes a fully validated method for the determination of temocillin in human serum, and its applicability in haemodialysis patients. Temocillin was extracted from human serum by a solid phase extraction methodology, and then assayed by reversed-phase HPLC with UV-detection. The method was validated according to the accuracy profile methodology, using total error to verify the trueness, precision and overall accuracy. It showed high specificity and precision and was accurate in the concentration range of 5–400 mg/L. LOD and LOQ were 1.2 and 5 mg/L, respectively. No interference with 30 co-administered drugs was evidenced. The method was successfully applied to clinical samples from haemodialysis patients, showing a high degree of dialysability of temocillin.
© 2013 Elsevier B.V. All rights reserved.

1. Introduction

Temocillin is a β-lactam antibiotic active against Gram-negative bacteria. Its spectrum covers *Enterobacteriaceae* (including strains producing β-lactamases), *Haemophilus influenzae* and *Neisseria* spp. [1], but not *Pseudomonas*. It is licensed for use in septicemia, urinary tract and lower respiratory tract infections [2]. Its interest has been recently renewed due to the increased incidence of organisms producing extended-spectrum β-lactamases, making it to become a sparing-drug for carbapenems [3]. Temocillin is administered as an isomeric mixture (both isomers rapidly interconvert in aqueous solution to the equilibrium mixture) [4]. Although not performed in routine, β-lactam therapeutic monitoring is considered of potential interest in specific situations, in order to optimize the dosing regimens for reducing the risk of treatment failures and of emergence of resistance [5]. Little is known about dosing and elimination rate of temocillin in haemodialysis patients, who may also present a wide pharmacokinetic variability for antibiotics eliminated by renal route [6]. Determining temocillin serum concentrations in haemodialysis patients is challenged by the fact they often receive several other medications and accumulate several acidic metabolites (uric acid, hippuric acid, indoxylsulfate, p-cresylglucuronide, p-cresylsulfate, indole-3-acetic acid, or 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid [7]) that can interfere in the assay [8]. There is no reported validated analytical method for temocillin assay in human serum. One study done in an intensive care setting [9] briefly describes the HPLC method used to analyze temocillin. However, when applied to samples from haemodialysis patients, it gave unsatisfactory results due to major interferences. The aim of the present study was therefore to establish and validate a reliable HPLC method to accurately quantify temocillin concentrations in the serum of patients with advanced kidney failure that could also be used while these patients were undergoing dialysis.

2. Materials and methods

2.1. Chemicals and reagents

Temocillin (NEGABAN®; ~68% R and ~32% S isomers) was provided by Eumedica s.a. (Brussels, Belgium). Ticarcillin disodium

* Corresponding author at: Pharmacologie cellulaire et moléculaire, Université catholique de Louvain, Avenue E. Mounier 73, B1.73.05, B-1200 Brussels, Belgium. Tel.: +32 2 7647378.
E-mail address: francoise.vanbambeke@uclouvain.be (F. Van Bambeke).

0731-7085/$ – see front matter © 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.jpba.2013.12.002

(∼55% R and ∼45% S isomers) used as internal standard (IS) was purchased from Sigma–Aldrich Inc. (St. Louis, MO, USA). HPLC-grade acetonitrile and other chemicals were obtained from VWR International (Radnor, PA, USA), Merck KGaA (Darmstadt, Germany) and Acros Organics (Subsidiary of Thermo-Fisher Scientific, Waltham MA, USA). Ultrapure water was obtained through a Milli-Q Academic apparatus (Millipore Corporation, Billerica, MA, USA).

2.2. Instrumentation and HPLC analysis

The HPLC system involved a Waters Alliance 2695 Separations Module equipped with a solvent degasser, a quaternary pump, and a temperature-controlled auto-sampler maintained at 4 °C, and was coupled to a Waters 2998 photodiode array (PDA) detector and operated with the Empower 2 software. Elution and resolution of the compounds were carried out with a RP-18 LiChrospher® column (250 × 4 mm, 100 Å, 5 μm) (Merck KGaA), with a isocratic gradient of sodium acetate (pH 7; 100 mM)–acetonitrile (95:5, v/v) at a flow rate of 1 mL/min, at 25 °C and in a 12 min run. The injection volume was 25 μL. PDA detection was monitored between 210 and 400 nm, with instrumental response expressed as the ratio between the areas of total temocillin (both isomers) and IS (both isomers) at 235 nm.

2.3. Calibrators and quality controls

Stock solutions of temocillin (10 mg/mL) were prepared in water, and used to prepare calibrators in human serum at 6 concentration levels in the 5–400 mg/L range. Four quality control (QC) samples were prepared from an independent stock solution. Both calibrators and QC samples were aliquoted, stored at −80 °C, and prepared with temocillin-free serum samples obtained from healthy donors (Centre de Transfusion de Woluwé-Saint-Lambert, Brussels, Belgium). The IS solution was prepared by reconstituting ticarcillin in ultrapure water to a final concentration of 1 mg/mL. Calibrators, QC samples, and IS solution were thawed on the day of use and discarded at the end of the day.

2.4. Sample preparation

All serum samples (calibrators, QC samples, or patient clinical samples) underwent a preanalytical procedure prior to HPLC analysis. It consisted in a newly developed solid-phase extraction (SPE) method, using Oasis® MAX cartridges (sorbent mass 1 cm^3/30 mg) placed in a vacuum manifold. Five hundred μL of samples were mixed to 500 μL of 4% orthophosphoric acid and 50 μL of IS, centrifuged (8600 g) for 20 min at 4 °C and the corresponding supernatant collected. Cartridges preconditioned successively with 1 mL of methanol and 1 mL of water were loaded with the supernatant, washed with 1 mL of sodium acetate (pH 7; 100 mM), 1 mL of methanol, and 1 mL of methanol:water:formic acid (39.2:58.8:2, v/v/v) solution. Temocillin and the IS were eluted with 1 mL of methanol:water:formic acid (78.4:19.6:2, v/v/v) solution. The eluates were transferred into an autosampler vial for HPLC analysis.

2.5. Method validation

Validation was designed according to the procedure of the *Société Française des Sciences et Techniques Pharmaceutiques* (SFSTP) [10,11]. The calibration experimental design was 6 × 2 × 3 (calibrators of 6 concentration levels, each one replicated twice over 3 days). The QC samples (4 concentration levels) were replicated 5 times over 3 days (4 × 5 × 3 experimental design). Data from calibrators were used to build the calibration curves (peak area ratios of temocillin/IS versus concentration), and the equation of the linear regression used to predict the actual concentrations of the QC samples. The accuracy profile methodology for method validation was applied [10,11]. Results were evaluated according to the FDA acceptance criteria for bioanalytical method validation [12]. Regarding specificity, 6 different blank serum samples were processed with and without temocillin and IS to ensure the absence of interfering peaks. In addition, serum from haemodialyzed patients not treated by temocillin but receiving a variety of other drugs (see details in Section 3) were examined for the presence of interfering substances by comparing chromatograms before and after spiking with temocillin. Trueness was expressed in absolute and relative bias (%) at each concentration of the QC samples [10,13,14]. Precision was evaluated as relative standard deviation (RSD%) values for repeatability and intermediate precision [14]. Accuracy was evaluated based on the two-sided 80% β-expectation tolerance intervals for the total measurement error, i.e. the sum of systematic and random errors of the analytical procedure [10,13,15]. Based on the trueness, precision and β-expectation tolerance intervals for each concentration level, an accuracy profile was constructed [10,13]. The LOQ was determined with the accuracy profile as the smallest concentration level where 80% β-expectation tolerance limits remained inside the ±20% acceptance limits [14,15]. The LOD was estimated using the mean intercept of the calibration model and the residual variance [16].

2.6. Clinical evaluation in haemodialysis patients

Applicability was tested in 4 haemodialysis patients who received a 2 g intravenous dose of temocillin immediately after a haemodialysis session preceding a 48 h interdialytic interval (protocol approved by the ethical committee of the AZ Sint-Jan Brugge-Oostende AV hospital in which patients were hospitalized [unique Belgian number: B049201215528]; all patients provided informed consent). Blood samples were processed locally (*AZ St-Jan*) for preparation of serum, followed by rapid freezing at −80 °C and transfer under dry-ice to the analytical laboratory (*Université catholique de Louvain*) where they were kept at −80 °C until analysis. To estimate temocillin dialysability, extraction ratio (ER) and haemodialysis clearance (CL_{HD}) were determined. ER was calculated as $(C_{s,IN}-C_{s,OUT})/C_{s,IN}$ where $C_{s,IN}$ and $C_{s,OUT}$ are the serum concentrations of temocillin flowing into and out of the dialyser, respectively. CL_{HD} was calculated as $CL_{HD} = Q_{dial}$ x ER, where Q_{dial} is the blood flow into and out of the dialyzer in mL/min. A low flux dialyzer Fresenius Helixone® FX8 with an A_{eff} 1.4 m^2 (Fresenius Medical Care AG & Co., KGaA, Gad Homberg, Germany) was used.

3. Results and discussion

3.1. Specificity and method optimization

Fig. 1 shows the chromatogram of a representative serum sample from a haemodialysis patient receiving temocillin (patient [a]) using this new method. Temocillin and IS peaks were well resolved, with retention times of approximately 6.8 min and 7.6 min (*R-S* isomers) for temocillin, and 10.1 min and 11.3 min (*R-S* isomers) for ticarcillin. Fig. 2 shows the chromatograms for serum samples of 3 random, non-infected, haemodialysis patients spiked with temocillin. Interfering peaks were systematically contaminating chromatograms obtained using the previously published method [9] but were no more observed with the current methodology. We attribute this improvement to the optimization of the solid phase extraction procedure (replacing the Oasis® HLB with



Fig. 1. Chromatogram of a representative human serum sample from a haemodialysis patient (patient [a]). The elution profiles of temocillin (*R* [TMO R] and *S* [TMO S]) isomers) are well separated from those other substances absorbing at the detection wavelength (235 nm) and from ticarcillin (internal standard with also the corresponding *R* (TIC R) and *S* (TIC S) isomers). Note that both isomers are biologically active and therapeutically equivalent because (i) the chiral atom (carrying the COO^- function in the lateral chain) is not directly part of the pharmacophore (β-lactam ring) and (ii) of fast interconversion of the two isomers. AU, arbitrary absorbance units.

MAX cartridges [specific for acidic compounds; yields better recovery]) and refining the wash steps to improve assay specificity. By tuning the proportions of methanol, water and formic acid, it was possible to determine a ratio of solvents that was able to elute acidic and interfering compounds but not temocillin. No interfering peaks were observed in the different serum samples analyzed in the presence of comedications (typically, 4–16 per patient), among the following drugs: alprazolam, amiodarone, amitriptyline, ampicillin, aspirin, calcium polystyrene sulfonate, calcium acetate, cefazolin, ciprofloxacin, colecalciferol, darbepoetin alfa, domperidone, fentanyl, fraxiparine, ibuprofen, insulin glargine, insulin aspart, levothyroxine, methylprednisolone, pantoprazole, paracetamol, phenprocoumon, pramipexole, pregabalin, omeprazole, oxycodone, piracetam, sevelamer, valproic acid, vancomycin, zolpidem.

3.2. Trueness, precision and accuracy

Trueness, precision and accuracy results are presented in Table 1. The magnitude of relative bias was ≤5.1%, showing an excellent trueness. The maximal RSD values for repeatability and highest intermediate precision were 2.3% and 5.1%, respectively (within regulatory requirements [15% for all concentration levels and 20% for LOQ; 12]). The method was considered as accurate in the 5–400 mg/L range (expected concentrations in serum samples) given the relative lower and upper 80% β-expectation tolerance limits (Fig. 3) [12,14]. The proposed method was linear within the studied concentration range of 5–400 mg/L (Fig. 3). The regression line fitted on the measured concentrations of the QC samples as a function of the introduced concentrations gives the following equation: $y = 0.985x + 0.361$, with $r^2 = 0.9985$.

3.3. Limit of quantification and detection

The lowest LOQ was 5 mg/L, corresponding to the smallest concentration level of the validation standards, as shown in Fig. 3. The LOD was 1.2 mg/L.

3.4. Stability

Stability studies (3 cycles of freeze–thaw [−80 °C/room temperature], short-term storage at room temperature [4 h] or in the autosampler [8 h at 4 °C]; long-term storage [6 months] at −80 °C) showed ≥90% recovery for long-term stability and ≥95% in other conditions (Table 2).

3.5. Application to clinical samples

Using this method, a preliminary analysis of the pharmacokinetic profile of temocillin in a representative haemodialysis patient (patient [a]) having received a bolus dose of 2 g showed that (i) peak level (∼160 mg/L) was of the same order of magnitude as those observed in ICU patients having received the same dose [9]; (ii) elimination was markedly slowed down with an apparent half-life at ∼26 h consistent with the renal insufficiency status of the patient; (iii) dialysis markedly accelerated the clearance of temocillin (Fig. 4). Temocillin dialysability was therefore investigated in samples from 4 patients (patients [a], [b], [c], [d]) showing a mean extraction ratio of 53.4% (range 31.9–71.1%; C_{IN}: 18–71 mg/L; C_{OUT}: 6–35 mg/L), and a mean CL_{HD} of 163.9 mL/min (range 83.9–218.3 mL/min). Temocillin pharmacokinetic studies in haemodialysis patients are scarce and have been performed in conditions that do not reflect the improved performance of modern dialyzers [17], making direct comparison of extraction





Fig. 2. Extracts of chromatograms of serum samples from 3 random haemodialysis patients not treated by temocillin. These samples were spiked with temocillin and treated by the methodology mentioned in a previous study [9] (upper panel), and the methodology described in the current study (lower panel). Note that the present method successfully eliminates assay interferences, considerably improving the specificity of the method. AU, arbitrary absorbance units.

rates or haemodialysis clearances questionable. The present study indicates that temocillin is extensively dialyzed, which is understandable based on its low molecular weight (414), its high water solubility (logD at pH 7.4 = −5.19 [calculated with REAXYS; http://www.reaxys.com]), and on the fact that protein binding (~60% for temocillin in ICU patients [9]) is generally decreased in renal failure. These data therefore emphasize the need for a post-dialysis replacement dose and for monitoring concentrations

Table 1
Assay validation results for quantification of total temocillin in human serum.

Sample	Nominal concentration (mg/L)	Trueness		Precision		Accuracy	
		Absolute bias (mg/L)	Relative bias (%)	Repeatability (RSD%)	Intermediate precision (RSD%)	β-Expectation tolerance intervals (mg/L)	Relative β-expectation tolerance limits (%)
LOQ	5	−0.256	−5.129	2.062	5.120	[4.223; 5.264]	[−16.095; 5.836]
QC1	15	−0.553	−3.687	2.336	4.006	[13.230; 15.664]	[−12.101; 4.734]
QC2	100	−0.497	0.497	2.205	2.410	[92.642; 108.353]	[−7.319; 8.314]
QC3	400	−5.889	−1.472	0.957	3.611	[363.344; 424.877]	[−9.279; 6.334]

LOQ, limit of quantification; RSD, relative standard deviation; QC, quality control.



Fig. 3. (A) Accuracy profile of the concentration (mg/L) of temocillin using a linear regression model. The continuous line is the relative bias, the gray lines are the upper and lower 80% β-expectation tolerance limits, and the dotted lines are the upper and lower FDA acceptance limits. The dots represent the relative error of the measured concentrations for each QC sample and are plotted with respect to their target concentration. (B) Linear profile of temocillin in human serum. The dotted lines are the upper and lower FDA acceptance limits, and the gray lines are the upper and lower 80% β-expectation tolerance limits, both expressed in concentration units. The dots represent the data points for the different QC samples across the concentration range 5–400 mg/L.

Table 2
Stability of temocillin in human serum.

Nominal concentration (mg/L)	Freeze–thaw stability*,a (%)	Bench top stability*,b (%)	Autosampler stability*,c (%)	6 Months stability*,d (%)
5	89.81 ± 3.20	95.67 ± 2.34	93.50 ± 2.46	93.73 ± 3.07
100	94.14 ± 1.05	94.67 ± 1.40	96.91 ± 7.26	90.97 ± 6.64
400	95.78 ± 0.12	95.40 ± 2.5	98.10 ± 1.98	88.96 ± 2.26

* Mean ± SD.
a 3 cycles of freeze–thaw [−80 °C/room temperature].
b Short-term at room temperature [4 h].
c Storage in the autosampler [8 h at 4 °C].
d Long-term storage [6 months] at −80 °C.



Fig. 4. Concentration–time profile for temocillin in the serum in a representative haemodialysis patient (patient [a]). An initial dose of 2 g was given at the end of a dialysis session (time 0). HD indicates the haemodialysis period (4 h).

to evaluate temocillin interdialytic loss while at the same time drawing attention to potentially sustained blood levels in patients with non-compensated renal insufficiency.

4. Conclusion

This paper is the first to describe a fully validated method enabling detection and quantification of temocillin in serum of patients with chronic kidney disease receiving multiple co-medications in a rapid, robust and reproducible manner. This method was successfully applied to clinical samples from haemodialysis patients, indicating the high degree of dialysability of temocillin and the need for a post-dialysis replacement dose or for therapeutic monitoring. Given the renewed interest in temocillin and its increased use in clinical practice, this method can probably serve as guide for application in other complex situations and may prove beneficial for patient management.

Conflict of interest

P.M.T. is an unpaid advisor to Eumedica s.a. The other authors have no conflict of interest.

Acknowledgments

We thank L. Dinaux from Waters Corporation, Zellik, Belgium, and Dr. A. Capron from the Cliniques Universitaires Saint Luc, Brussels, Belgium for useful suggestions and support. Temocillin was a gift from Eumedica s.a., Manage, Belgium. This work was supported by Fonds de la Recherche Scientifique Médicale (F.R.S.M.; Grant No. 3-4-597-06) and by Region Wallonne (project TEMOEXPAND 1217668). A.C.M.B. and A.S. are employees of the Université catholique de Louvain, and S.J.V., of the AZ Sint-Jan Brugge-Oostende A.V.; F.V.B. is Senior Research Associate of the Fonds de la Recherche Scientifique (F.R.S.-FNRS). P.M.T. was unpaid.

References

[1] K. Jules, H.C. Neu, Antibacterial activity and beta-lactamase stability of temocillin, Antimicrob. Agents Chemother. 22 (1982) 453–460.
[2] Temocillin Summary of Product Characteristics. UK Medicines and Healthcare products Regulatory Agency (MHRA): Electronic Medicines Compendium (eMc), 2012, Available at http://www.medicines.org.uk (accessed 18.08.12/last updated: 03.04.12).
[3] D.M. Livermore, P.M. Tulkens, Temocillin revived, J. Antimicrob. Chemother. 63 (2009) 243–245.
[4] E.A. Guest, R. Horton, G. Mellows, B. Slocombe, A.J. Swaisland, T.C. Tasker, A.R. White, Human pharmacokinetics and antimicrobial activities of the temocillin epimers, Drugs 29 (Suppl. 5) (1985) 154–161.
[5] Y. Hayashi, J. Lipman, A.A. Udy, M. Ng, B. McWhinney, J. Ungerer, K. Lust, J.A. Roberts, Beta-lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia, Int. J. Antimicrob. Agents 41 (2013) 162–166.
[6] D. Cohen, G.B. Appel, B. Scully, H.C. Neu, Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis, Antimicrob. Agents Chemother. 24 (1983) 529–532.
[7] J. Boelaert, F. Lynen, G. Glorieux, S. Eloot, M. Van Landschoot, M.A. Waterloos, P. Sandra, R. Vanholder, A novel UPLC-MS–MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients, Anal. Bioanal. Chem. 405 (2013) 1937–1947.
[8] R. Vanholder, R. De Smet, G. Glorieux, A. Argiles, U. Baurmeister, P. Brunet, W. Clark, G. Cohen, P.P. De Deyn, R. Deppisch, B. Descamps-Latscha, T. Henle, A. Jorres, H.D. Lemke, Z.A. Massy, J. Passlick-Deetjen, M. Rodriguez, B. Stegmayr, P. Stenvinkel, C. Tetta, C. Wanner, W. Zidek, Review on uremic toxins: classification, concentration, and interindividual variability, Kidney Int. 63 (2003) 1934–1943.
[9] R. De Jongh, R. Hens, V. Basma, J.W. Mouton, P.M. Tulkens, S. Carryn, Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection, J. Antimicrob. Chemother. 61 (2008) 382–388.
[10] P. Hubert, J.J. Nguyen-Huu, B. Boulanger, E. Chapuzet, P. Chiap, N. Cohen, P.A. Compagnon, W. Dewe, M. Feinberg, M. Lallier, M. Laurentie, N. Mercier, G. Muzard, C. Nivet, L. Valat, Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal – Part I, J. Pharm. Biomed. Anal. 36 (2004) 579–586.
[11] P. Hubert, J.J. Nguyen-Huu, B. Boulanger, E. Chapuzet, P. Chiap, N. Cohen, P.A. Compagnon, W. Dewe, M. Feinberg, M. Lallier, M. Laurentie, N. Mercier, G. Muzard, C. Nivet, L. Valat, E. Rozet, Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal – Part II, J. Pharm. Biomed. Anal. 45 (2007) 70–81.
[12] Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2001, Available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed 12.11.12/last updated 2001).
[13] E. Rozet, C. Hubert, A. Ceccato, W. Dewe, E. Ziemons, F. Moonen, K. Michail, R. Wintersteiger, B. Streel, B. Boulanger, P. Hubert, Using tolerance intervals in pre-study validation of analytical methods to predict in-study results. The fit-for-future-purpose concept, J. Chromatogr. A 1158 (2007) 126–137.
[14] P. Hubert, J.J. Nguyen-Huu, B. Boulanger, E. Chapuzet, N. Cohen, P.A. Compagnon, W. Dewe, M. Feinberg, M. Laurentie, N. Mercier, G. Muzard, L. Valat, E. Rozet, Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal – Part III, J. Pharm. Biomed. Anal. 45 (2007) 82–96.
[15] E. Rozet, A. Ceccato, C. Hubert, E. Ziemons, R. Oprean, S. Rudaz, B. Boulanger, P. Hubert, Analysis of recent pharmaceutical regulatory documents on analytical method validation, J. Chromatogr. A 1158 (2007) 111–125.
[16] J.N. Miller, J.C. Miller, Calibration methods in instrumental analysis: regression and correlation, in: J.N. Miller, J.C. Miller (Eds.), Statistics and Chemometrics in Analytical Chemistry, Pearson Education, Harlow, UK, 2010, pp. 110–153.
[17] J. Boelaert, R. Daneels, M. Schurgers, G. Mellows, A.J. Swaisland, A.M. Lambert, H.W. Van Landuyt, Effect of renal function and dialysis on temocillin pharmacokinetics, Drugs 29 (Suppl. 5) (1985) 109–113.